Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks

SERA PROGNOSTICS, INC.

Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.
Revenue minimal: $10k Q4, $81k full year; company remains pre-commercial.
Cash $95.8M at Dec 31, 2025; expects to fund operations through 2028.
PRIME study published Jan 2026: PreTRM test reduced preterm births <32 wks by 56%, NICU admissions by 20%.
Completed $57.5M follow-on offering Feb 2025; added CMO Dr. Inglis, CCO Anderson in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SERA PROGNOSTICS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.

Period: the fourth quarter and fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 18, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025 and providing business highlights.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SERA PROGNOSTICS, INC. filing history →

Source: SEC EDGAR

accession 0001534969-26-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.